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Summary 
G-CSF stimulates mobilization of hematopoietic progenitor cells (HPCs) from bone 
marrow by disrupting the CXCR4/SDF-1α retention axis. We show here that distinct 
factors and mechanisms regulate the mobilization of endothelial (EPCs) and stromal 
progenitor cells (SPCs). Pre-treatment of mice with VEGF did not disrupt the 
CXCR4/SDF-1α chemokine axis but stimulated entry of HPCs into the cell cycle via 
VEGFR1, reducing their migratory capacity in vitro and suppressing their mobilization 
in vivo. In contrast, VEGF pre-treatment enhanced EPC mobilization via VEGFR2 in 
response to CXCR4 antagonism. Furthermore, SPC mobilization was detected when 
the CXCR4 antagonist was administered to mice pre-treated with VEGF, but not G-
CSF. Thus, differential mobilization of progenitor cell subsets is dependent upon the 
cytokine milieu that regulates cell retention and proliferation. These findings may 
inform studies investigating mechanisms that regulate progenitor cell recruitment in 
disease and can be exploited to provide efficacious stem cell therapy for tissue 
regeneration. 
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Introduction 
The bone marrow is a reservoir of progenitor cells, including haematopoietic 
progenitor cells (HPCs), fibrocytes, mesenchymal stem cells (MSCs) and endothelial 
progenitor cells (EPCs). In response to disease or tissue injury these cells are 
mobilized from the bone marrow and recruited into tissues where they contribute 
either to disease progression or tissue repair (Takahashi et al., 1999; Orlic et al., 
2001; Rankin 2008). Thus, for example, fibrocyte recruitment detrimentally contributes 
to fibrosis and tissue remodelling in diseases such as idiopathic lung fibrosis and 
ischemic cardiomyopathy (Philips et al., 2004; Haudek et al., 2006). In contrast, EPCs 
recruited into ischemic tissues promote angiogenesis and thereby contribute to tissue 
regeneration (Asahara et al., 1997; 1999;Takahashi et al., 1999; Nolan et al., 2008). 
Further, the identity of an EPC type, which is distinct from a HPC phenotype has now 
been reported (Hur et al., 2004; Yoder et al., 2007; Nolan et al., 2007) Indeed, EPCs 
have been demonstrated to repair damaged myocardium and improve cardiac function 
(Kocker et al., 2001). Mesenchymal stem cells have the capacity to differentiate into 
adipocytes, chondrocytes and osteocytes and potentially other cell types including 
epithelial, myocardial or neuronal cells (Pittenger et al., 1999). It is thought, therefore, 
that MSCs may be used to promote tissue regeneration in the treatment of diseases 
such as osteogenesis imperfecta and Parkinsons (Hess & Borlongan 2008; Bielby et 
al., 2007). Additionally MSCs have been reported to have immunosuppressive 
properties and as such they may be therapeutically useful for the treatment of 
autoimmune diseases (Le Blanc & Ringden 2007). The therapeutic application of 
these distinct sub-populations of stem cells in the context of specific diseases is 
therefore widely anticipated. Currently however, there are both practical and technical 
complications associated with harvesting, isolation, ex vivo expansion and delivery of 
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these cells. An alternative strategy for stem cell therapy is to stimulate the mobilization 
of stem cells from the bone marrow into the circulation, thereby circumventing these 
issues. This approach has been established clinically with respect to the treatment of 
donors over 3-5 days with the cytokine G-CSF to mobilize of HPCs for bone marrow 
transplants (BMT) (Cashen et al., 2004).  
Mobilization of progenitor cells is a multi-stage process; with initial release from their 
bone marrow niche followed by active migration across the bone marrow sinusoidal 
endothelium. The chemokine axis SDF-1α/CXCR4 is critically involved in the retention 
of haematopoietic stem cells within the bone marrow (Levesque et al., 2003). At a 
molecular level, G-CSF has been shown to act by disrupting the SDF-1α/CXCR4 
retention axis, both by reducing CXCR4 expression on HPCs and levels of SDF-1α in 
the bone marrow (Levesque et al., 2003; Semerad et al., 2002). This knowledge has 
led to the development of CXCR4 antagonists as HPC mobilizing agents. In contrast 
to G-CSF, such antagonists work acutely, mobilizing HPCs within an hour. Moreover, 
we and others have shown that chronic G-CSF therapy combined with acute 
administration of a CXCR4 antagonist synergistically enhances HPC mobilization from 
the bone marrow (Broxmeyer et al., 2005; Martin et al., 2006). This combination 
therapy has recently shown greater efficacy compared to G-CSF alone in phase III 
clinical trials for BMT (Calandra et al., 2008). While it has been shown that 
administration of a CXCR4 antagonist alone increases the circulating numbers of 
EPCs and improves tissue perfusion following ischemia in animals (Capoccia et al., 
2006; Shepherd et al., 2006) it is not known whether G-CSF therapy in combination 
with acute administration of the CXCR4 antagonist acts synergistically to mobilize 
EPCs.  
In addition to factors that disrupt the retention of EPCs in the bone marrow, 
EPCs may also be mobilized by factors, such as VEGF, that stimulate their migration 
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(Asahara et al., 1997). Indeed treatment of mice with VEGF has been shown to 
increase the circulating numbers of EPCs (Asahara et al., 1999), however, the relative 
efficacy of VEGF versus G-CSF alone or in combination with other mobilizing reagents 
has not been specifically assessed with respect to EPC mobilization. There is 
evidence that bone marrow-derived MSCs contribute to tissue regeneration, 
suggesting that these cells are also mobilized in response to tissue injury, however the 
factors and mechanisms regulating the mobilization of MSCs are currently unknown 
(Rochefort et al., 2006; Au et al., 2008). 
We have previously shown that different sub-populations of leukocytes are selectively 
mobilized from the bone marrow in response to specific blood-borne mediators via 
distinct mechanisms (Palframan et al., 1998; 1998a; Martin et al., 2003; Wengner et 
al., 2008). In this study we have identified pathways regulating the differential 
mobilisation of discrete populations of progenitor cells. 
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Results 
The CXCR4 antagonist mobilizes discrete populations of progenitor cells in 
mice pre-treated with G-CSF or VEGF. 
 
It has previously been established that G-CSF and the CXCR4 antagonist act 
synergistically to mobilize HPCs from the bone marrow (Broxmeyer et al., 2005; Martin 
et al 2006). In the first experiment we examined whether this treatment protocol 
similarly mobilized maximal numbers of EPCs and stromal progenitor cells (SPCs). 
Furthermore we investigated whether the profile and numbers of progenitors in the 
blood changed if mice were pre-treated with VEGF instead of G-CSF. We determined 
circulating numbers of HPCs, EPCs and SPCs one hour after the administration of the 
CXCR4 antagonist, AMD3100, to mice pre-treated over 4 days with either G-CSF, 
VEGF or vehicle control.  Administration of the CXCR4 antagonist alone increased 
circulating numbers of HPCs and EPCs within 1 hour (Figures 1b and 1c, and 
Shepherd et al., 2006). Interestingly, SPCs were not detected in the blood. G-CSF 
pre-treatment of mice also increased circulating numbers of HPCs, and to a lesser 
extent EPCs. (Figures 1b and 1c). Intriguingly, no SPCs were detected (Figure 1d). 
Whilst G-CSF pre-treatment followed by acute administration of the CXCR4 antagonist 
synergistically enhanced circulating numbers of HPCs (Figure 1b and Broxmeyer et 
al., 2005; Martin et al 2006), no such synergism (or even additive effect) was apparent 
for EPC mobilization (Figure 1c).  Furthermore, SPCs could not be detected. Of note, 
EPCs were scored after 21 days in culture and were shown to be CD34, VEGFR2, 
VE-Cadherin, and vWF positive (Supplementary Figures 1, 2 and  3). Furthermore 
these EPCs stained positively with GS-lectin, took up acetyl-LDL and formed tubules 
in vitro. These EPCs are therefore equivalent to the so-called late outgrowth EPCs 
that have the capacity to form vessels in vivo (Hur et al., 2004; Yoder et al., 2007; 
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Nolan et al., 2007; Hirschi et al., 2008). Importantly the mobilized EPCs did not 
express CD115, CD14, or CD45  and are thus distinct from both HPCs and the EPCs 
that are of monocytic origin (Supplementary Figures 1, 2 and  3) (Hur et al., 2004; 
Yoder et al., 2007; Nolan et al., 2007; Hirschi et al., 2008) 
 
VEGF administration can increase circulating number of cells with an EPC phenotype 
(Asahara et al., 1997). Similarly we observed an increase in EPC numbers following 
VEGF treatment of mice over 4 days (Figure 1c). Moreover, a more than additive 
increase in EPC numbers was observed when  the CXCR4 antagonist was 
administered acutely to mice pre-treated with VEGF as compared to mice treated with 
VEGF alone or administered a CXCR4 antagonist alone (P<0.05 Figure 1c). In 
contrast to G-CSF, VEGF-treatment did not increase circulating numbers of HPCs 
(Figure 1b). Further, we found unexpectedly that VEGF pre-treatment profoundly 
suppressed circulating numbers of HPCs (77% reduction) mobilized by the CXCR4 
antagonist (P<0.01, Figure 1b). Uniquely, VEGF-treatment combined with the CXCR4 
antagonist led to a significant increase in circulating SPCs (CFU-F P<0.001, Figure 
1d). Importantly, mobilized SPCs displayed the same antigen expression phenotype 
as bone marrow-derived SPCs (Supplementary figure 4a) which on expansion 
exhibited tri-lineage differentiation potential (Supplementary Figure 4c-e). Mobilized 
SPCs were plastic adherent cells, shown to be CD29 and CD105, positive; yet were 
CD34 and CD45 negative (Supplementary Figure 4b). Mobilized SPCs had the same 
characteristics as murine mesenchymal stem cells (Phinney et al., 1999; Pittenger et 
al., 1999; Mereilles & Nardi 2003).  Mobilized SPCs were also negative for VE-
Cadherin and vWF and were therefore distinct from mobilized EPCs (Supplementary 
Figure 4b). These results suggest that fundamentally different mechanisms regulate 
the mobilization of phenotypically distinct HPCs, EPCs and SPCs. 
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G-CSF and VEGF pre-treatment differentially regulate the rate of egress of 
progenitor cell sub-populations from the bone marrow in response to a CXCR4 
antagonist 
 
To determine whether the differences in circulating numbers of progenitors cells was 
due specifically to differences in their rate of egress out of the bone marrow we used 
an in situ perfusion model of the murine hind-limb developed by our group to directly 
assess mobilization. In this system, the femoral artery and vein are cannulated in situ 
such that the femur and tibia bone marrow are perfused in isolation. Mobilized cells 
are then collected via the femoral vein (Martin et al., 2003; 2006; Wengner et al., 
2008). This technique allows direct comparisons of the number of cells mobilized over 
a defined period of time, without the complications of progenitor cell trafficking into 
other tissues including their return to the bone marrow. Mice were pre-treated with 
vehicle, G-CSF or VEGF for 4 days. On day 5, the femoral artery was infused for 10 
minutes with either vehicle or the CXCR4 antagonist and cells mobilized were 
collected over a period of 1 hour (Figure 2a: experimental protocol).  When the 
CXCR4 antagonist was infused into vehicle pre-treated mice, HPCs and EPCs, but not 
SPCs were mobilized from the bone marrow (P<0.001, Figure 2b-2d). Pre-treatment of 
mice with G-CSF over 4 days enhanced the basal rate of HPC and EPC egress from 
the bone marrow (P<0.001, Figure 2b and 2c). However, G-CSF pre-treatment did not 
lead to the mobilization of SPCs (Figure2d). As indicated above, G-CSF pre-treatment 
followed by the CXCR4 antagonist led to a synergistic mobilization of HPCs (P<0.001, 
Figure 2b), but not EPCs (Figure 2c). Furthermore, no SPCs were mobilized with the 
combination of G-CSF pre-treatment followed by the CXCR4 antagonist (Figure 2d). 
VEGF pre-treatment resulted in significant EPC mobilization (P<0.001, Figure 2c), 
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however, HPCs and SPCs were not mobilized (Figures 2b and 2d). Furthermore, 
VEGF pre-treatment almost completely suppressed HPC mobilization induced by 
infusion of the CXCR4 antagonist (P<0.001 Figure 1e, 75% reduction), whilst an 
additive effect was observed for EPC mobilization (P<0.01 Figure 2c). Uniquely with 
this treatment regime, SPCs were mobilized (P<0.001, Figure 2d). These experiments 
definitively show that changes in circulating numbers of progenitors are due to 
changes in their rate of egress from the bone marrow. 
 
Acute administration of cytokines does not result in the differential mobilization 
of HPCs, EPCs and SPCs in response to the CXCR4 antagonist. 
 
The selective mobilization of EPCs and SPCs achieved by treating mice over 4 days 
with VEGF followed by administration of the CXCR4 antagonist was not reproduced 
when mice were treated acutely with a combination of VEGF and the CXCR4 
antagonist. Infusion of either G-CSF or VEGF directly into the femoral artery for 10 
minutes and collection up to 60 minutes mobilized both HPCs and EPCs (P<0.001  
Supplementary Figures 5a and 5b). However, acute administration of VEGF (in 
contrast to VEGF pre-treatment over 4 days) did not inhibit the mobilization of HPCs 
with a CXCR4 antagonist and acute administration of G-CSF did not act synergistically 
with the CXCR4 antagonist to mobilize HPCs (Supplementary Figures 5a and 5b). 
Further, neither growth factor, when administered acutely or in combination with the 
CXCR4 antagonist led to mobilization of SPCs (Supplementary Figure 5c). This 
suggested that the ability of G-CSF and VEGF to promote the differential mobilization 
of progenitor cell subsets is dependent on changes to the bone marrow environment 
or the progenitor cell phenotype that occurs over a number of days.  
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VEGF-treatment does not alter bone marrow morphology or progenitor cell 
frequency 
We next determined whether treatment of mice over 4 days with VEGF or G-CSF 
affected the number of progenitor cells in the bone marrow. The total number of cells 
in the femurs of mice treated with VEGF (1.07±0.11x107 cells/femur) or G-CSF 
(1.41±0.28x107 cells/femur) was not significantly different compared to control mice 
(1.19±0.07x107 cells/femur). Furthermore, no difference was observed in the 
frequency of HPCs (Figure 3a), EPCs (Figure 3b) or SPCs (Figure 3c) in the bone 
marrow of VEGF-treated mice compared to controls. However, G-CSF-treatment did 
cause a significant reduction in the number of bone marrow EPCs (P<0.001 Figure 
3b), and an increase in the number of SPCs (P<0.05 Figure 3c).  
 
To determine whether VEGF-treatment of mice affected the gross morphology of the 
bone marrow, we performed histological analysis of bone marrow in mice treated over 
4 days with PBS or VEGF. As shown in Figure 3d we observed no differences in the 
gross morphology, the number of sinusoidal blood vessels, or endothelial integrity 
(Figure 3d). Thus, with no gross morphological changes occurring to the bone marrow 
of mice treated with VEGF which might affect cellular egress, we next examined 
whether the molecular retention mechanisms had been disturbed. 
 
VEGF- treatment does not alter the expression of CXCR4 on HPCs or EPCs. 
The CXCR4/SDF-1α chemokine axis is critical for the retention of HPCs in the bone 
marrow (Levesque et al., 2003). Indeed, G-CSF mobilizes HPCs by reducing their 
expression of CXCR4 and decreasing levels of SDF-1α in the bone marrow. To 
determine whether VEGF similarly mobilized progenitor cells by disrupting this 
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chemokine axis, we analyzed CXCR4 expression on progenitor cells and SDF-1α 
levels in the bone marrow of VEGF and G-CSF-treated mice. In mice treated with G-
CSF we observed a significant reduction in levels of SDF-1α (P<0.001, Figure 4a) and 
CXCR4 expression on HPCs (P<0.05, Figure 4b), however, the expression of CXCR4 
on EPCs was unchanged (Figure 4c), suggesting that G-CSF does not directly effect 
EPC retention. This explains why G-CSF is far more effective in mobilizing HPCs than 
EPCs (Figures 1b-1c and 2b-2c).  In contrast, VEGF-treatment did not alter the 
expression of CXCR4 on either HPCs or EPCs (Figures 4b, and 4c). Moreover, SDF-
1α levels in bone marrow supernatant following VEGF-treatment were not altered 
(Figure 4a). Whilst the anti-CXCR4 antibody used here is targeted to the epitope 
matching the first 63 amino acids starting from the N-terminus of a GST-NCXCR4 
fusion protein (Forster et al., 1998), it is noted that G-CSF will cleave part of this 
epitope, and therefore inhibiting the function of CXCR4 (Levesque et al., 2003). Thus 
reduced antibody binding will therefore indicate either a reduction in the expression of 
the functional receptor, or an absolute loss of the receptor. Thus we can conclude that 
VEGF-treatment does not inhibit the function of CXCR4 or affect it’s cell-surface 
expression. 
 
These data indicate that VEGF-treatment does not disrupt the CXCR4/SDF-1α 
retention pathway and therefore explains why VEGF alone does not mobilize HPCs 
from the bone marrow.   
 
VEGF- treatment inhibits HPC but not EPC chemotaxis towards SDF-1α. 
Mobilization is dependent on cellular migration across the bone marrow sinusoidal 
endothelium. Given that VEGF did not alter CXCR4 expression on HPCs or EPCs 
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(Figure 4b and 4c) we examined the ability of bone marrow derived HPCs and EPCs 
from G-CSF or VEGF-treated mice to undergo chemotaxis towards SDF-1α in vitro 
since in PBS-treated mice, both HPCs and EPCs migrated to SDF-1α (P<0.001 Figure 
4d-4g). G-CSF-treatment lead to further increased migration of HPCs and EPCs to 
SDF-1α (P<0.001 Figure 4d and 4e). In contrast, VEGF-treatment abolished the ability 
of HPCs to migrate to SDF-1α but had no effect on EPC migration (Figures 4f and 4g). 
The suppression of HPC chemotaxis towards SDF-1α suggested that HPCs from 
VEGF-treated mice were refractory to migratory stimuli despite expressing CXCR4.  
 
VEGF-treatment does not affect the ability of neutrophils to undergo chemotaxis 
Neutrophils, like progenitor cells, are also retained within the bone marrow by the 
CXCR4/SDF-1α axis, and as such can be mobilized by G-CSF-treatment or CXCR4 
antagonism (P<0.001, Figure 5a and Martin et al., 2003). We therefore investigated 
whether VEGF pre-treatment of mice suppressed neutrophil mobilization as we 
observed for HPC mobilization (Figure 1b and 2b). As shown in Figure 5a, VEGF pre-
treatment profoundly suppressed neutrophil mobilization in response to the CXCR4 
antagonist (P<0.05, 92% reduction). This effect was not seen when VEGF was 
administered acutely to mice (Figure 5b). We therefore investigated whether the 
migratory capacity of neutrophils after VEGF-treatment was impaired in a similar 
manner to HPCs. During inflammatory reactions, neutrophils are rapidly mobilized 
from the bone marrow by ELR+ CXC chemokines (e.g. KC) which stimulate neutrophil 
migration across the bone marrow sinusoidal endothelium (Martin et al., 2003; 
Wengner et al., 2008). Surprisingly, KC-induced mobilization of neutrophils in vivo was 
completely abrogated in mice pre-treated with VEGF (P<0.001, Figure 5c). However, 
VEGF-treatment did not affect either the proportion of Gr-1+ bone marrow neutrophils 
expressing CXCR2 (Figure 5d), or the ability of bone marrow neutrophils to migrate 
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towards KC in vitro (Figure 5e). Thus, whilst VEGF pre-treatment suppressed both 
HPC and neutrophil mobilization in vivo; neutrophils, but not HPCs, retained the ability 
to undergo chemotaxis in vitro, suggesting that the suppression of HPC chemotaxis 
was particular to their character as progenitor cells compared to neutrophils which are 
terminally differentiated cells. Analysis of bone marrow revealed a significant reduction 
in absolute numbers of mature neutrophils (band and segmented nuclei) following 
VEGF-treatment compared to controls (Figure 5f). It is unclear, however, whether this 
reduction in the bone marrow reserve accounts for the dramatic reduction in neutrophil 
mobilization.  
 
VEGF- treatment stimulates entry of HPCs bit not EPCs into the cell cycle  
Activation of HPCs via VEGFR1 is required for cell survival and cell-cycling (Hattori et 
al., 2001; Gerber et al., 2002).  Since a refractoriness of HPCs to migrate is a feature 
of cell-cycling (Bowie et al., 2006; Uchida et al., 1997; Roberts & Metcalf 1995), we 
next tested whether VEGF-treatment of mice stimulates HPC proliferation. 
Examination of HPC colonies grown from bone marrow of VEGF-treated mice 
revealed a significant increase in both their cellular content and size compared to 
controls (Figures 6a, 6b), suggesting that VEGF promotes proliferation of CFU-HPC 
ex vivo.  In vivo analysis revealed that VEGF-treatment led to a significant increase in 
the percentage of BM-HPCs (Lin- Sca-1+ cells) in the S/G2/M proliferative phase of the 
cell-cycle (Figure 6c). In direct contrast, VEGF-treatment did not alter the percentage 
of CD34+ VEGFR2+ EPCs in the S/G2/M phase of the cell-cycle (Figure 6d). Moreover, 
whilst VEGF has the capacity, as a primary growth factor, to alter the cell cycle status 
of HPCs (Gerber et al., 2002), we show, as previously described,  that G-CSF does 
not stimulate entry of either HPCs (Figure 6c) or EPCs (Figure 6d) into the S/G2/M 
phase of the cell cycle (McKinstry et al., 1997; Nicola et al., 1985; Colvin et al., 2007), 
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However, as shown by others G-CSF does promote expansion and differentiation of 
granulocytes as evident by the increased numbers of neutrophils in the bone marrow 
(Figure 5f) (McKinstry et al., 1997; Lord et al., 1989; 1991). 
 
HPCs are known to express VEGFR1, therefore we next investigated whether the 
effect of VEGF in stimulating the entry of HPCs into the cell cycle in vivo was 
mediated via this receptor (Supplementary figure 1). We show here that in vivo 
administration of an antibody directed against VEGFR1 completely suppressed the 
VEGF-stimulated entry of HPCs into the cell cycle (Figure 6e).  
 
VEGFR1 antagonism reverses VEGF-induced suppression of HPC mobilization 
in response to a CXCR4 antagonist. 
Since activation of VEGFR1 was demonstrated to lead to an accumulation of Lin- Sca-
1+ HPCs within the proliferative phase of the cell cycle (Figure 6e). We next 
determined whether blocking of VEGFR1 in vivo would reverse VEGF-induced 
suppression of HPC mobilization in response to a CXCR4 antagonist. We show that 
administration of a VEGFR1 blocking mAb to VEGF-treated mice, completely restored 
the ability of the CXCR4 antagonist to mobilize HPCs from the bone marrow ( 
P<0.001, Figure 7a). In contrast, anti-VEGFR1 antibody administration did not affect 
VEGF-induced mobilization of EPCs (Figure 7b). This data indicate that VEGF acting 
via VEGFR1 stimulates the entry of HPCs into the cell cycle and blocks their 
mobilization from the bone marrow, while effects of VEGF on VEGFR2 stimulate the 
mobilization of EPCs. Hence the differential effects of VEGF in regulating HPC and 
EPC mobilization are due to actions via distinct receptors. 
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Discussion 
We show here, for the first time, that the mobilization of progenitor cell subsets, are 
differentially regulated by growth factors affecting their retention and cell cycle status. 
Specifically we show that whilst maximal mobilization of HPCs occurs when the 
CXCR4 antagonist is administered to mice pre-treated with G-CSF, under these 
conditions, EPC mobilization is sub-maximal and SPCs are not mobilized. In contrast, 
when mice are pre-treated with VEGF, the acute administration of a CXCR4 
antagonist stimulates mobilization of EPCs and SPCs while suppressing HPC and 
neutrophil mobilization. As such, the profile of progenitor cells in the blood changes 
dramatically dependent on the treatment protocol.  
The retention of HPCs and mature neutrophils within the bone marrow is dependent 
on the SDF-1α/CXCR4 chemokine axis. Thus, mechanisms that disrupt this axis 
promote the egress of HPCs and neutrophils (Martin et al., 2003; Levesque et al., 
2003). Consistent with previous reports, we show here, that G-CSF mobilizes both 
neutrophils and HPCs, by reducing their expression of CXCR4 and decreasing levels 
of SDF-1α within the BM (Levesque et al., 2003; Wengner et al., 2008). In contrast, G-
CSF alone mobilized only modest numbers of EPCs and no additive or synergistic 
effects were observed when mice pre-treated with G-CSF were administered the 
CXCR4 antagonist. There are no reports that EPCs express G-CSF receptors. 
Further, in this study G-CSF had no effect on the expression of CXCR4 by EPCs. This 
data suggests that G-CSF does not have a direct effect on EPCs, which may explain 
why mobilization of EPCs with the CXCR4 antagonist could not be enhanced by pre-
treatment of mice with G-CSF.  
 
Unexpectedly, pre-treatment of mice with VEGF suppressed the mobilization of both 
neutrophils and HPCs in response to the CXCR4 antagonist. This was not due to a 
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change in CXCR4 expression by these cells. HPCs mobilized by G-CSF have been 
found to be exclusively in the Go/G1 phase of cell cycle, whereas HPCs remaining in 
the bone marrow are actively cycling (Bowie et al., 2006; Uchida et al., 1997; Roberts 
et al., 1995). This may be explained by the fact that proliferating HPCs cannot migrate, 
a necessary step in their mobilization from the bone marrow. Here we show, for the 
first time, that the exogenous administration of VEGF to naïve mice stimulates the 
entry of HPCs into the S/G2/M phase of the cell cycle in vivo and thereby severely 
impairs the migratory capacity of these cells, in vitro. Furthermore, as a consequence 
of their inability to migrate, the mobilization of HPCs by the CXCR4 antagonist is 
completely abrogated in mice treated with VEGF. It has previously been proposed that 
there are two pools of HPCs, a quiescent dormant reserve of HPCs residing in the 
endosteal niche that accounts for approximately one third of the HPCs and a 
‘mobilizable’ pool of HPCs, that have the potential to proliferate, residing in the 
vascular niche adjacent to the sinsusoidal endothelium (Wilson et al., 2007). We 
propose that in stimulating HPCs in the vascular niche to enter the cell cycle VEGF 
has a profound effect on HPC mobilization.  
It has previously been shown that in vivo treatment of immuno-suppressed mice with a 
blocking mAb to VEGFR1 reduces cell cycling of HPCs and the survival of HSCs 
following engraftment (Gerber et al., 2002 Hattori et al., 2002).  This suggests that in 
this model endogenous VEGF acting via VEGFR1, expressed by HPCs, can regulate 
the proliferation/survival of HPCs/HSCs (Gerber et al., 2002). In this study we show 
that that selective blockade of VEGFR1 abolishes the ability of exogenous VEGF to 
stimulate HPC entry into the cell cycle in vivo and restores the ability of the CXCR4 
antagonists to mobilize HPCs from the bone marrow.  
Interestingly, the mobilization of neutrophils in response to both the CXCR4 antagonist 
and the chemokine, KC, was dramatically inhibited in mice pretreated with VEGF. This 
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is not due to an effect on cell proliferation as these are terminally differentiated cells, 
indeed neutrophils harvested from the bone marrow of VEGF-treated mice migrated 
normally in response to chemokines. This suggests that VEGF may affect egress of 
mature cells from the bone marrow by other, as yet identified mechanisms. Tissue 
specific expression of VEGF has been shown to induce the perivascular expression of 
SDF-1α (Grunewald et al., 2006). It is possible, therefore, that neutrophils may be 
retained within the vascular niche of the bone marrow following chronic VEGF-
treatment due to locally increased SDF-1α expression, acting to re-enforce the 
retention of neutrophils via the CXCR4/SDF-1α axis (Martin et al 2003).  
 
VEGF stimulates the migration and promotes survival of endothelial cells via signals 
emanating from VEGFR2 (Gerber et al., 1998). Interestingly, we observed that VEGF- 
treatment of mice did not stimulate the proliferation of VEGFR2+/CD34+ EPCs and as 
such EPCs in the bone marrow of these mice retained their ability to migrate towards 
chemokines in vitro and to be mobilized in response to CXCR4 antagonists in vivo. 
We show here that, anti-VEGFR1 antibody administration did not affect VEGF-induced 
mobilization of EPCs, indicating that EPC mobilization stimulated by VEGF is indeed 
mediated via VEGFR2. Hence the differential effects of VEGF in regulating HPC and 
EPC mobilization are mediated via distinct receptors, VEGFR1 on HPC and VEGFR2 
on EPCs. The ability of VEGF to differentially promote the cell cycling of HPCs as 
compared to EPCs, explains why EPCs can be selectively mobilized by the CXCR4 
antagonist in mice treated over 4 days with VEGF. Consistent with this data is the 
finding that acute administration of VEGF alone or in combination with the CXCR4 
antagonist did not selectively mobilize EPCs from the bone marrow. Mechanistic 
differences between acute and chronic VEGF exposure are unknown, however acute 
administration of high doses of VEGF, delivered by adenovirus, is associated with 
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capillary leakiness which may facilitate the escape of progenitor cells from the BM 
(Moore et al., 2001). Indeed adVEGF has been shown to induce the non-selective 
mobilization of myeloid cells, HPCs, and EPCs, as observed here with acute VEGF 
administration (Hattori et al., 2001). 
 
The G-CSF-treatment protocol used here, has been evaluated to promote cardiac 
regeneration in patients with MI (Orlic et al., 2001; 2001a; Kocker et al., 2001; Powell 
et al., 2005; Zolnhofer et al., 2006; Ince et al., 2005; Ripa et al., 2006; Ellis et al., 
2006; Hill et al., 2005). These trials have been disappointing with only 1 out of 5 trials 
showing any significant clinical benefit (Zolnhofer et al., 2006; Ince et al., 2005; Ripa 
et al., 2006; Ellis et al., 2006; Hill et al., 2005). As we reveal here, such limited clinical 
success might be because G-CSF administration is not a particularly efficacious 
regime for mobilizing EPCs or SPCs which may be important for cardiac regeneration. 
Indeed, we have shown that G-CSF treatment actually decreases the number of EPCs 
in bone marrow, thus depleting the available reservoir for tissue recruitment and 
revascularization. Further, G-CSF also stimulates neutrophil mobilization, which may 
exacerbate the inflammatory response and negatively impact cardiac regeneration 
(Hill et al., 2005; Kang et al., 2004; Zernecke et al., 2008). In this study we have 
identified a treatment protocol that selectively mobilizes EPCs and SPCs, but not 
HPCs or neutrophils, from the bone marrow. Future studies will investigate the 
therapeutic efficacy of this mobilizing regime for cardiac regeneration following 
myocardial infarction. 
 
Taken together, the results presented here indicate that different factors and 
molecular mechanisms regulate the mobilization of discrete populations of progenitor 
cells from the bone marrow. This has far reaching implications for our understanding 
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of mechanisms regulating the selective recruitment of different populations of 
progenitor cells in disease and the development of therapeutic strategies to mobilize 
specific sub-populations for regenerative medicine. 
 
 
Figure Legends 
Figure 1: G-CSF and VEGF pre-treatment differentially regulate circulation of 
progenitor cells in response to a CXCR4 antagonist. 
a, Experimental protocol. Mice were pre-treated with G-CSF, VEGF, or vehicle (PBS) 
once daily for 4 days (100μg/kg i.p.). 24 hours after the last injection, mice were 
administered a CXCR4 antagonist (AMD3100 5mg/kg i.p, closed bars) or vehicle 
(PBS, open bars). 60 minutes later, blood was taken for analysis of circulating: b, 
CFU-HPC; c, CFU-EPC; and d, CFU-SPC.  CFU-HPC, CFU-EPC, and CFU-SPC are 
shown as number of colonies per ml blood. n=5-8 mice per group. Data: means± 
s.e.m. *: P<0.05, **: P<0.01, ***: P<0.001 between selected groups. 
 
Figure 2: G-CSF and VEGF pre-treatment differentially regulate mobilization of 
progenitor cells in response to a CXCR4 antagonist. 
a, overview of procedures set up for identifying the direct mobilization of progenitor 
cells from the femoral bone marrow. Mice were pre-treated with G-CSF, VEGF, or 
vehicle (PBS) once daily for 4 days (100μg/kg i.p.). 24 hours after the last injection, 
mice underwent perfusion of the right hind limb. CXCR4 antagonist (AMD3100 0.1mM, 
closed bars) or vehicle (PBS, open bars) were then infused directly into the femoral 
artery for 10 minutes. The hind limb was then perfused for a further 50 minutes to 
allow collection of b, CFU-HPC; c, CFU-EPC; or d, CFU-SPC; via the femoral vein.  
CFU-HPC, CFU-EPC, and CFU-SPC are shown as total number of colonies collected 
in the perfusate. n=5-8 mice per group. Data: means± s.e.m. *: P<0.05, **: P<0.01, ***: 
P<0.001 between selected groups. 
 
Figure 3: VEGF-treatment does not alter the number of progenitor cells residing 
in the bone marrow, or the morphology of the bone marrow. 
Mice were treated with G-CSF, VEGF, or vehicle (PBS), administered once daily for 4 
days (100μg/kg i.p.). 24 hours after the last injection, bone marrow was aspirated for 
the enumeration of a, CFU-HPC bone marrow frequency; b, CFU-EPC bone marrow 
frequency; and c, CFU-SPC bone marrow frequency. Femurs from other mice were 
fixed in situ and processed for: d, bone marrow morphology of vehicle and VEGF-
treated mice, at x20, and x60 objective. n= 4-8 per group. Data: mean± s.e.m. *: 
P<0.05, ***: P<0.001 between selected groups. 
 
Figure 4: VEGF-treatment does not alter the expression of CXCR4 on HPCs or 
EPCs. However, VEGF suppress bone marrow-derived HPC chemotaxis towards 
SDF-1α 
Mice were treated with G-CSF, VEGF, or vehicle (PBS), administered once daily for 4 
days (100μg/kg i.p.). Bone marrow was aspirated on day 5 and harvested cells were 
used to determine a, SDF-1α levels in bone marrow supernatant as determined by 
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ELISA; b, % of bone marrow Lin- Sca-1+ cells expressing CXCR4; and c, % of bone 
marrow CD34+ VEGFR2+ cells expressing CXCR4. Harvested cells were also utilized 
in the following chemotaxis assays: d, number of HPCs; and e, EPCs undergoing 
chemotaxis towards 30nM SDF-1α. Cells taken from bone marrow of mice treated with 
G-CSF (closed bars) or vehicle (PBS, open bars). f, number of HPCs; and g, EPCs 
undergoing chemotaxis towards 30nM SDF-1α. Cells taken from bone marrow of mice 
treated with VEGF(closed bars) or vehicle (PBS, open bars). n= 4-8 per group. Data: 
mean± s.e.m. *: P<0.05, ***: P<0.001 between selected groups. 
 
 
Figure 5: VEGF pre-treatment suppresses neutrophil mobilization, but does not 
affect their ability to undergo chemotaxis. 
Mice were pre-treated with G-CSF, VEGF, or vehicle (PBS), administered once daily 
for 4 days (100μg/kg i.p.). 24 hours later these mice underwent perfusion of the right 
hind limb. CXCR4 antagonist (AMD3100 0.1mM, closed bars) or vehicle (PBS, open 
bars) were then infused directly into the femoral artery for 10 minutes. The hind limb 
was then perfused for a further 50 minutes to allow collection of a, neutrophils via the 
femoral vein. In other perfusion experiments, CXCR4 antagonist or PBS were infused 
in addition to VEGF (50nM), G-CSF (50nM), or vehicle (PBS) into the femoral artery of 
naïve mice for 10 minutes. The hind limb was again perfused for a further 50 minutes 
to allow b, collection of neutrophils. In some groups of mice pre-treated with VEGF 
over 4 days, KC (30μg/kg i.v.) was administered 24 hours after the last injection of 
VEGF and c, circulating neutrophil numbers (determined by blood smears) were 
counted 60 minutes after administration of KC  (closed bars) or vehicle (PBS, open 
bars). d, % of Gr-1high neutrophils expressing CXCR2; and e, Neutrophil chemotaxis 
towards KC (30nM) of neutrophils taken from bone marrow of mice pre-treated with 
VEGF, or vehicle (PBS).  f, leukocyte counts of bone marrow taken from mice pre-
treated with VEGF, G-CSF or vehicle (PBS). n=4-8 mice per group. Data: mean± 
s.e.m. *: P<0.05, ***: P<0.001 between selected groups. 
 
 
Figure 6: VEGF pre-treatment, acting via VEGFR1 enhances HPC cell cycling 
compared to EPCs. 
a, number of cells per colony; and b, mean colony area; of CFU-HPC grown for 12 
days in methocult. Cells were taken from bone marrow of mice treated (once daily for 
4 days) with G-CSF, VEGF, or vehicle (PBS) (100μg/kg i.p.). Representative 
histograms of PI stain of DNA content for Lin- Sca-1+ HPCs, c.i,  PBS-treated, c.ii 
VEGF-treated, c.iii G-CSF-treated, and c.iv, % of Lin- Sca-1+ HPCs residing in S/G2/M 
phase of the cell-cycle. Representative histograms of PI stain of DNA content for 
CD34+ VEGFR2+ EPCs d.i,  PBS-treated, d.ii VEGF-treated, d.iii G-CSF-treated, and 
d.iv, % of CD34+ VEGFR2+ EPCs residing in S/G2/M phase of the cell-cycle. In 
another experiment, mice were treated with anti-VEGFR1 antibody (2.5mg/kg) or 
control IgG on days 1 and 3, 30 minutes before VEGF administration. Representative 
histograms of PI stain of DNA content for Lin- Sca-1+ HPCs, e.i,  PBS-treated, e.ii 
VEGF-treated + anti-IgG, e.iii VEGF-treated + anti-VEGFR1 antibody, and e.iv, % of 
Lin- Sca-1+ HPCs residing in S/G2/M phase of the cell-cycle.  n=4- 7 per group. Data: 
mean± s.e.m. *: P<0.05, **: P<0.01 between selected groups.  
 
Figure 7: VEGFR1 blockade reverses VEGF-induced suppression of HPC 
mobilization in response to a CXCR4 antagonist.  
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Mice were pre-treated with VEGF, or vehicle (PBS) once daily for 4 days (100μg/kg 
i.p.). Mice pre-treated with VEGF were additionally administered control IgG or anti-
VEGFR1 antibody (2.5mg/kg) on days 1 and 3, 30 minutes before VEGF 
administration.  24 hours after the last injection, mice were administered a CXCR4 
antagonist (AMD3100 5mg/kg i.p, closed bars) or vehicle (PBS, open bars). 60 
minutes later, blood was taken for analysis of circulating: a, CFU-HPC; b, CFU-EPC. 
c, Representation of the divergent roles of G-CSF and VEGF treatment on HPC and 
EPC status in bone marrow. n= 4 per group. Data: mean± s.e.m. *: P<0.05, ***: 
P<0.001 between selected groups.  
 
 
 
Experimental Procedures. 
 
Reagents 
Recombinant murine chemokines and growth factors KC/CXCL1, SDF-1α/CXCL12, G-
CSF, and VEGF were from PeproTech (London, U.K.). For in vivo blocking 
experiments, anti-murine polyclonal VEGFR1 antibody (AF471) was purchased from 
RnD Systems (Abingdon, UK). Control rat IgG was purchased from Jackson 
Immunoresearch (Newmarket U.K.) The CXCR4 antagonist AMD3100, propidium 
iodide (PI), Triton X, and RNase were purchased from Sigma Aldrich (Poole, U.K.). 
Dulbecco’s Modified Eagles medium (DMEM) was purchased from Life Sciences 
(Paisley, U.K.). Methocult and supplements was obtained from StemCell Technologies 
(Vancouver, Canada). EGM-2 basal media and supplements were purchased from 
Lonza (Wokingham, U.K.). 3μm pore size transwell chemotaxis plates were purchased 
from Neuroprobe (Gaithersburg U.S.A.). 5μm pore size transwell chemotaxis inserts 
were purchased from Corning (New York U.S.A). Anti-human/mouse CXCL12/SDF-1 
antibody, biotinylated anti-human/mouse CXCL12/SDF-1 antibody, and streptavidin-
HRP for ELISA were purchased from RnD Systems (Abingdon, U.K.). Rat anti-mouse 
CD34-FITC antibody (IgG2a) was purchased from AbD Serotec (Nottingham U.K.). 
Rat anti-mouse Sca-1-APC (Ly-6A/E) antibody (IgG2a) and rat anti-mouse VEGFR2-
APC (Flk-1) antibody (IgG2a) were purchased from eBioscience (Wembley U.K.). Rat 
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anti-mouse CD11b-FITC antibody (IgG2b), Rat anti-mouse Gr-1-FITC (Ly-6G and Ly-
6C) antibody (IgG2b), rat anti-mouse CD45R/B220-FITC antibody (IgG2a), rat anti-
mouse CD3e-FITC antibody (IgG2a), rat anti-mouse TER119-FITC antibody (IgG2b), 
rat anti-mouse CXCR4-PE antibody (IgG2b) were purchased from BD Pharmingen 
(Oxford U.K.). Rat anti-mouse CXCR2-APC antibody (IgG2a) was purchased from 
RnD Systems (Abingdon, U.K.). Rat anti-mouse CD16/CD32 Fc-block (IgG2b) was 
purchased from BD Pharmingen (Oxford U.K.). The following isotype control  
antibodies were purchased: rat IgG2a-FITC, IgG2b-FITC, and rat IgG2b-PE (BD 
Pharmingen, Oxford U.K.). Rat IgG2a-APC was purchased from RnD Systems 
(Abingdon, U.K.). For immunohistochemistry, the following antibodies were used: goat 
anti-mouse VEGFR1 antibody, rabbit anti-mouse VEGFR2 antibody, rat antimouse 
CD34 antibody, goat anti-mouse VE-Cadherin antibody were purchased from Santa-
Cruz Biotech (Santa Cruz, U.S.A.). Rat anti-mouse CD45 antibody, rat anti-mouse 
CD29 antibody, rat anti-mouse CD105 antibody were purchased from BD Pharmingen 
(Oxford, U.K.). rat anti-mouse CD115 antibody was purchased from eBioscience 
(Wembley, U.K.). Rabbit anti-human vWF antibody was purchased from DAKO 
(Glostrup, Denmark). The following isotype controls were used: Rat IgG1 from BD 
Pharmingen (Oxford, U.K.), goat IgG and rabbit IgG from Santa-Cruz Biotech (Santa 
Cruz, U.S.A.). The following fluorescently labeled secondary antibodies were used: 
donkey anti-goat Alexafluor 568 antibody, goat anti-rat Alexafluor 594 antibody, goat 
anti-rabbit Alexafluor 488 antibody were purchased from Molecular Probes (Paisley, 
U.K.) 
 
Pre-treatment with G-CSF or VEGF 
Female BALB/c mice were purchased from Harlan (Oxford, United Kingdom). Mice, at 
the age of 8-10 weeks were administered VEGF (2.5 μg/mouse i.p.), G-CSF (2.5 
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μg/mouse i.p.), or vehicle on 4 consecutive days. 24 hours after the last injection, mice 
were administered a CXCR4 antagonist (AMD3100, 5mg/kg i.p), KC (30μg/kg i.v.)  or 
vehicle and blood was collected via cardiac puncture 60 minutes later for enumeration 
of circulating leukocyte, HPC, EPC, and stromal progenitor cell levels. In other 
experiments, mice pre-treated with G-CSF or VEGF were used for in situ perfusion of 
the mouse hind limb as explained below. All studies were carried out under the United 
Kingdom’s Animals (Scientific Procedures) Act of 1986 and local ethical approval from 
Imperial College, London. 
 
Administration of anti-VEGFR1 antibody 
Mice were administered anti-VEGFR1 or control IgG (2.5mg/kg i.p. Ohki et al., 2005) 
30 minutes before VEGF administration on days 1 and 3 of the 4 day VEGF-treatment 
protocol.  
 
In situ perfusion of mouse hind limb 
On day 5 following pre-treatment of growth factors, mice were anaesthetized and the 
femoral artery and vein exposed. The hind limb was isolated by occlusion of the 
external iliac artery, superficial epigastric and muscular branch. Polyethylene cannulae 
(Portex, London, UK) were immediately inserted into the femoral artery and vein as 
previously described (Martin et al., 2003; 2006; Wengner et al., 2008). Perfusion 
buffer was infused via the arterial cannula and removed from the venous cannula 
using a Minipuls peristaltic pump (Anachem, Luton, UK). The hind limb was perfused 
for an initial 2 minutes to remove remaining blood from the vasculature and then 
perfused for a further 60 min with vehicle alone or the CXCR4 antagonist (AMD3100, 
0.1mM), infused over the first 10 minutes using an infusion/withdrawal pump (Harvard 
Instruments, U.K.).  
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In some studies the effects of acute administration of G-CSF or VEGF on HPC, EPC, 
and stromal progenitor cell mobilization were examined. G-CSF or VEGF (50nM) were 
added to the perfusion buffer for an initial 10 minutes. 
 
Analysis of mobilized cells from the bone marrow in blood and perfusate. 
The perfusate was centrifuged and re-suspended in DMEM +20%FBS. In some 
experiments citrated blood was obtained via cardiac bleed and lysed for red blood 
cells. Bone marrow and perfusate cytospins, and blood smears were stained using 
DiffQuik for the enumeration of mononuclear cells, eosinophils, and neutrophils. Bone 
marrow, perfusate and lysed blood were then used for assays outlined below to 
enumerate HPCs (CFU-HPC), EPCs (CFU-EPC), SPCs (CFU-F).  
 
CFU-HPC assay 
5x 104 cells were added to Methocult medium (Stem cell technologies) supplemented 
with specific cytokines and growth factors to enable formation of CFU-HPC. Mobilized 
cells were incubated for 11 days before quantification. Further characteristics of CFU-
HPC colonies were obtained on day 12, namely the mean number of cells in each 
colony, and the mean colony area. The mean colony area (mm2) was determined by 
image analysis using Scion Image analysis program (NIH). The cell number was 
determined by diluting colonies grown in Methocult into DMEM (to disperse the 
methylcellulose) and aspirating the colonies into a single cell suspension before 
obtaining a cell count. Cells taken from HPC colonies and immunostained showed 
CD1155, CD34, CD45, VEGFR1 positive cells, but were negative for VEGFR2, VE-
Cadherin, and von Willebrand Factor (vWF) (Supplementary Figure 1) 
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CFU-EPC assay 
5x105 cells were added to EPC colony media (EGM-2 basal media + supplements, 
and additional VEGF: 60μg/L, and FBS: 16% final concentration) on fibronectin-coated 
plates. Dishes were incubated for 7 days before media was changed, and then 
incubated for a further 14 days before the enumeration of EPC colonies (CFU-EPC). 
These “late outgrowth” EPC colonies exhibited a cobblestone morphology and by 
immunohistochemical analysis (Protocol: Supplementary Methods section) expressed 
CD34, VEGFR2, VE-Cadherin, and vWF (Supplementary Figure 1) stained positively 
with GS-lectin and were able to uptake acetyl-LDL(Supplementary Figure 2a), as 
reported by others (Nolan et al., 2007; Yoder et al., 2007; Hur et al., 2004). 
Importantly, ‘late outgrowth’ CFU-EPC did not express CD115, CD14 or CD45 
(Supplementary Figure 1), and are therefore not of a monocyte-macrophage lineage 
(Hirschi et al., 2008). Moreover, CFU-EPC were able to form tubules in an in vitro EC 
Matrix angiogenesis assay (See Supplementary Methods section) whereby complete 
mesh-like structures formed after 18 hours in culture (Supplementary Figure 2b-d). 
 
CFU-SPC (CFU-F) assay  
5x105 cells were added to Mesencult media including supplements (Stemcell 
Technologies). Dishes were incubated for 7 days before media was changed, and 
then incubated for a further 14 days before the enumeration of SPC colonies (CFU-F). 
Plastic adherent bone marrow derived SPCs were shown to express CD29 and 
CD105 and were negative for CD45 and CD34 (Supplementary Figure 4a) as 
demonstrated in previous studies on stromal progenitor cells (Phinney et al., 1999; 
Pittenger et al., 1999). Furthermore, expanded SPC colonies were assessed for their 
ability to differentiate into other cell types (Supplementary Methods Section), and were 
capable of mesenchymal tri-lineage differentiation into adipocytes (Supplementary 
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Figure 3c), osteocytes (Supplementary Figure 3d) and chondrocytes (Supplementary 
Figure 3e) These progenitor cells exhibit all the characteristics of murine 
mesenchymal stem cells (Pittenger et al., 1999) 
 
The total number of colony forming units mobilized was calculated according to the 
number of colonies per plate x by the total number of leukocytes mobilized/ number of 
cells seeded. 
 
Flow cytometry analysis of chemokine receptor expression on cells residing in bone 
marrow. 
For flow cytometric analysis, cells were re-suspended in FACS buffer. To identify 
neutrophils in the bone marrow, surface expression of the granulocyte marker Ly-
6G/Ly6C (Gr-1) was determined. Neutrophils were identified as Gr-1high positive cells 
with a characteristic high side scatter profile. HPCs residing in the BM were selected 
as being negative for lineage (Lin-) markers: CD3e, CD11b, CD45R, Ly-76, and Gr-1 
and positive for Sca-1 (Lin- Sca-1+ cells) (Gerber et al., 2002; Uchida et al., 1997). 
EPCs residing in the BM were selected as being positive for both CD34 and VEGFR2 
(CD34+ VEGFR2+ cells) (Asahara et al., 1997; Yoon et al., 2005). Furthermore, 
neutrophils were stained for the surface expression of CXCR2, whilst Lin- Sca-1+ cells 
and CD34+ VEGFR2+ cells were stained for the cell surface expression of CXCR4. 
Samples were then washed and then quantified on a FACSAria cell sorter (BD 
Biosciences, Oxford, United Kingdom) and analysed using FACSDiva software. 
 
PI staining to determine cell cycle status 
Lin- Sca-1+ cells and CD34+ VEGFR2+  cells were analysed to determine their cell 
cycling status using a propidium iodide (PI) stain. Unfixed cells were initially stained as 
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explained above to identify their cell type before the addition of 50μL PI (100μg/ ml), 
and 50μL RNase (100μg/ ml) was added to minimise PI binding to RNA. 5 minutes 
before flow cytometric analysis, 50μL of 0.1% Triton X (in saline) was added to sample 
to permeabilize the cell membrane and allow DNA binding. Analysis of flow cytometry 
data of PI-stained cells was performed using FACSDiva software. A dotplot of PI-
Width against PI-Area was recorded.  Aggregates of cells were detected as cells 
having a larger PI-W profile and were not included in the gate. A PI-A histogram of the 
gated cells showed the first peak to represent cells in G0/G1, the second peak cells in 
G2/M, and the in between area S phase cells. To calculate the percentage of cells 
undergoing active cell cycling, a marker was set to exclude the G0/G1 peak and the 
percentage of cells in S/ G2/ M was calculated. 
 
Bone marrow  histology 
Femoral bone marrow was fixed by infusion of 2.5%  glutaraldehyde  in a modified 
Krebs-Ringers buffer for 15 minutes using the in situ perfusion technique previously 
described (Martin et al., 2003; 2006; Wengner et al., 2008). The femur was removed 
and placed in fresh glutaraldehyde fixative before being processed and stained with 
toluidine blue. 
 
In vitro chemotaxis assays of neutrophils, HPCs and EPCs  
Bone marrow-derived neutrophils were tested for migration towards KC (30nM) using 
3μm pore sized transwell chemotaxis plates as previously described (Wengner et al., 
2008). To measure HPC and EPC migration towards SDF-1α, murine bone marrow 
cells (2x106 cells)  were placed in the upper chamber of transwell inserts (5μm pore 
size Corning). These in turn were placed in individual wells of a 24 well cell culture 
plate with 30nM SDF-1 α added. Chambers were incubated for 4 hours at 37˚c and 
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migrated cells were then placed in methocult or EPC colony media as described 
above for the enumeration of CFU-HPC and CFU-EPC respectively.  
 
SDF-1α ELISA on bone marrow supernatants 
Supernatant from bone marrow aspirates was analyzed for SDF-1α content as per the 
recommended protocol for the capture and detection antibody (MAB350 and BAF310 
respectively . RnD systems).  
 
Statistical Analysis 
Data are expressed as mean± SEM. In vivo mobilization data and in vitro chemotaxis 
data were analysed using two-way analysis of variance (ANOVA), followed by 
Bonferroni multiple-comparisons test. Flow cytometry data of PI stain were analysed 
using one-way ANOVA, followed by Bonferroni multiple-comparisons test. Flow 
cytometry data of chemokine receptor expression were analysed using Student’s T-
test. All analyses were conducted using the GraphPad Prism statistical package 
(version 4.0; Graph Pad, San Diego, CA). P values less than 0.05 were considered 
significant. 
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Supplementary Methods 
 
Immunohistochemistry of HPC, EPC, and SPC colonies. 
                                  
EPC and SPC colonies grown in chamber slides, and cytospins of cells from HPC 
colonies were fixed in ice cold methanol for 10 minutes, before washing in PBS + 1% 
BSA. Slides were blocked for 30 minutes with PBS+10%BSA. Slides were then 
stained with the following antibodies: goat anti-mouse VEGFR1, rabbit anti-mouse 
VEGFR2, rat anti-mouse CD34, goat anti-mouse VE-Cadherin, rat anti-mouse CD45, 
rat anti-mouse CD29, rat anti-mouse CD105, rat anti-mouse CD115, rabbit anti-human 
vWF, or goat anti-mouse CD14. The following isotype controls were used: Rat IgG1, 
goat IgG, and rabbit IgG. After 90 minutes, slides were washed and incubated with the 
following appropiate fluorescently labeled secondary antibodies: donkey anti-goat 
Alexafluor 568 antibody, goat anti-rat Alexafluor 594 antibody, goat anti-rabbit 
Alexafluor 488 antibody. After a further wash, slides were mounted onto coverslips 
using glycerol based mounting medium containing a 4’,6-diamidino-2-phenylindole 
(DAPI) counterstain. Slides were analyzed using a fluorescent microscope (Leica, 
Germany). 
 
Staining of EPC colonies with GS-Lectin and uptake of Ac-LDL 
DIL-labeled Acetylated-low density lipoprotein (Ac-LDL) was added to EPC media 
(5μg/ml) and cells were incubated for 4 hours at 37˚c. Colonies were then washed in 
PBS and fixed with 2% PFA for 10 minutes before incubation with fluoroscein 
conjugated griffonia-simplicifolia (GS)-lectin (10μg/ml in PBS) for 60 minutes. Colonies 
were then analyzed using a fluorescent microscope (Leica, Germany). 
 
 35
In vitro angiogenesis assay 
The ability of EPCs to form tubules was assessed using an in vitro angiogenesis 
assay (Madri & Pratt 1986; Salani et al., 2000). EC Matrix Gel solution and EC Matrix 
diluent buffer (Chemicon) were mixed in a ratio of 9:1 at 4˚c. 50μl was then added 
wells of a pre-cooled 96 well plate and this was then incubated at 37˚c for 1 hour to 
allow the matrix solution to solidify. EPC colonies were harvested by trypsinization and 
re-suspended in EPC growth media at a density of 1x105 cells/ml and seeded (150 μl) 
onto the surface of the polymerized matrix. Cells were then incubated for 24 hours, 
and cellular network structures were fully developed by 12-18 hours. 
 
 
Tri-lineage differentiation of SPC colonies 
 
To induce differentiation of SPCs into adipogenic and osteogenic lineages appropriate 
differentiation media was added to SPC colonies. Basic differentiation media 
consisted of 10% FBS, penicillin/ streptomycin and fungizone. Osteogenic 
differentiation was induced by adding 50μg/ml ascorbic acid-2-phosphate, 10nM 
dexamethasone and 10mM β-glycerol to basic media (Eslaminejad et al., 2006). 
Adipogenic differentiation was induced by adding 50μg/ml indomethacine, 100nM 
dexamethasone and 10ng/ml insulin to basic media (Zuk et al., 2002). Control cultures 
were incubated in basic media. The differentiation media was replaced three times a 
week for a period of 20 days. To promote chondrogenic differentiation the micromass 
culture technique was used (Eslaminejad et al., 2006, Pevsner-Fischer et al., 2006, 
Pittenger et al., 1999). SPCs were detached by trypsinization and pelleted in a conical 
polypropylene tube. Chondrogenic differentiation media consisting of basic media 
supplemented with 10ng/ml TGF-β, 50nM ascorbic acid-2-phosphate and 6.25 μg/ml 
insulin was added to the cells (Pevsner-Fischer et al., 2006). The chondrogenic 
differentiation media was changed three times a week for a period of 2-3 weeks. 
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To confirm differentiation of SPCs to mesenchymal lineages, osteocytes, adipocytes 
and chondrocytes were stained with cell type specific dyes as reported in previous 
publications (Pittenger et al., 1999, Zuk et al., 2002). SPCs cultured in osteogenic 
media were stained with Alizarin red. This dye is used to demonstrate the presence of 
calcium. Interaction of Alizarin dye with calcium ions results in a bright red stain. SPCs 
cultured in adipogenic media were stained with Oil red O (Sigma-Aldrich) which is a fat 
soluble dye that stains triglycerides and lipids of fixed cells with a deep red colour. 
Cells cultured in chondro-inductive media were stained using Toluidine Blue, which 
stains the background blue (orthochromatic staining) and the areas of cartilage matrix 
red-purple (metachromatic staining).  
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Supplementary Figure 1: Immunostaining of bone marrow-derived HPCs and 
EPCs. 
Colonies of HPCs a, and EPCs b, derived from bone marrow cells, were stained for 
the expression of CD115 (red), CD34 (red), CD45 (red), VEGFR1 (red), VEGFR2 
(green), VE-Cadherin (red), vWF (green). Nuclei were counterstained with DAPI 
(blue). 
 
Supplementary Figure 2: GS-Lectin stain, AC-LDL uptake, and tubule formation 
of bone marrow derived EPCs. 
a, CFU-EPC were stained for GS-Lectin (green) and their ability to uptake Ac-LDL 
(red). Resuspended EPCs were added to a angiogenesis supporting matrix gel for the 
evaluation of tubule formation. b, EPCs 1 hour after addition to matrix; c, tubule 
formation was apparent after 18 hours in culture, when luminal structures were 
evident, d.    
 
                                                                                                                                                              
Supplementary Figure 3: Immunostaining of mobilized EPCs. 
Colonies of mobilized EPCs were stained for the expression of CD115 (red), CD14 
(red), CD45 (red), CD34 (red), VEGFR1 (red), VEGFR2 (green), VE-Cadherin (red), 
and vWF (green). Nuclei were counterstained with DAPI (blue). 
 
Supplementary Figure 4: Immunostaining of bone-marrow-derived SPCs, 
mobilized SPCs, and tri-lineage differentiation potential.  
a, colonies of SPCs derived from bone marrow cells were stained for the expression of 
CD29 (red), Cd105 (red), CD45 (red), CD34 (red),VEGFR1 (red), VEGFR2 (green), 
and VE-Cadherin (red). b, colonies of mobilized SPCs were stained for the expression 
of CD29 (red), CD105 (red), CD45 (red), CD34 (red),VEGFR1 (red), VEGFR2 (green), 
VE-Cadherin (red), and vWF (green). Nuclei were counterstained with DAPI (blue). 
Expanded colonies subjected to specific differentiation media revealed SPCs were 
able to display a tri-lineage differentiation potential towards c, adipocytes (oil red O); 
d, osteocytes (Alizarin red); e, chondrocytes (toluidine blue). 
 
 
Supplementary Figure 5: Acutely administered VEGF or G-CSF do not 
selectively modulate progenitor cell mobilization either alone, or in combination 
with a CXCR4 antagonist. 
Mice underwent perfusion of the right hind limb. CXCR4 antagonist (AMD3100 0.1mM, 
closed bars) or vehicle (PBS, open bars) alone, or in combination with G-CSF (50nM), 
or VEGF (50nM) were then infused directly into the femoral artery for 10 minutes. The 
hind limb was then perfused for a further 50 minutes to allow collection of a, CFU-
HPC; b, CFU-EPC; and c, CFU-SPC via the femoral vein.  CFU-HPC, CFU-EPC , and 
CFU-SPC are shown as total number of colonies per perfusate. n=5-8 mice per group. 
Data: means± s.e.m. **: P<0.01, ***: P<0.001 between selected groups. 
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